Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: Response, survival, and prognostic factors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 5, 2010, Pages 474-480

  Gupta, Sanjay ^a   Bedikian, Agop Y ^a   Ahrar, Judy ^a   Ensor, Joe ^a   Ahrar, Kamran ^a   Madoff, David C ^a   Wallace, Michael J ^a   Murthy, Ravi ^a   Tam, Alda ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Hepatic artery chemoembolization; Liver metastases; Ocular melanoma; Prognostic variables; Survival

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; IMATINIB; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MITOMYCIN; PACLITAXEL; TEMOZOLOMIDE; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; EYE MELANOMA; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; EYE TUMOR; HEPATIC ARTERY; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOEMBOLIZATION, THERAPEUTIC; EYE NEOPLASMS; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 78049443606     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b4b065     Document Type: Article

References (33)

1. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151-166.
2. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26:624-633.
3. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
4. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389; discussion 90.
5. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 2004;11:290-297.
6. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
7. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89:1561-1568.
8. Fournier GA, Albert DM, Arrigg CA, et al. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol. 1984;102:80-82.
9. Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004;14:217-222.
10. Carrasco CH, Wallace S, Charnsangavej C, et al. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA. 1986;255:3152-3154.
11. Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297-304.
12. Sharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol. 2008; 190:99-104.
13. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133: 177-184.
14. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974-976.
15. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15: 2589-2595.
16. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16: 1103-1111.
17. Hofmann MA, Coll SH, Kuchler I, et al. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology. 2007;215:10-16.
18. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer. 1993;71:2995-3005.
19. Heimdal K, Hannisdal E, Gundersen S. Regression analyses of prognostic factors in metastatic malignant melanoma. Eur J Cancer Clin Oncol. 1989; 25:1219-1223.
20. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. IV: prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126-134.
21. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
22. Unger JM, Flaherty LE, Liu PY, et al. Gender and other survival redictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer. 2001;91:1148-1155.
23. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219-2223.
24. Kamat PP, Gupta S, Ensor JE, et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol. 2008;31:299-307.
25. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma: an analysis of related prognostic factors. Cancer. 1997;79:2345-2353.
26. Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer. 2006;107:2833-2841.
27. Tellez C, Benson AB III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998;82:1250-1259.
28. Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in liver metastases after transcatheter arterial embolization or arterial infusion. Acta Radiol. 1990;31:269-274.
29. Carrasco CH, Chuang VP, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology. 1983;149:79-83.
30. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104:1590-1602.
31. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors-a retrospective singlecenter analysis. Digestion. 2003;68:94-101.
32. Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003;180: 1379-1384.
33. Roche A, Girish BV, de Baere T, et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology. 2004;51:1751-1756.